Get Free Checker

Forth

[ US /ˈfɔɹθ/ ]
[ UK /fˈɔːθ/ ]
NOUN
  1. a river in southern Scotland that flows eastward to the Firth of Forth

How To Use Forth In A Sentence

  • Shah went forth with her for a distance of three parasangs; after which he bade farewell to her and the Wazir and those with him, and returned to his home in gladness and safety. The Book of The Thousand Nights And A Night
  • Sadly, none of a myriad of ingenious contraptions, despite inventors' claims, puts forth more energy than it absorbs.
  • I realized how our leadership brings forth mediocre organizations and dispirited people.
  • Entry forms for the forthcoming Community Games should have been received by now.
  • By convention, this assent is always forthcoming.
  • What of it if Winter has another snow-storm or two up his sleeve?I take my staff and fare forth to greet Spring with three dogs at my heels.
  • When the dork came to bat, he was waving the bat back and forth with the label aimed straight at the pitcher. WHY is the FOUL POLE FAIR?
  • As a prelude to the book, Dr Mitra has compiled an audio CD of some of the works that will appear in the forthcoming book.
  • A straw poll conducted at the end of the meeting found most people agreed with Mr Forth.
  • Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Somaxon's business, including, without limitation, Somaxon's interpretation of its communications and interactions with the FDA relating to the requirements for approval of the NDA for Silenor, and the FDA's agreement with such interpretation; Somaxon's interpretation of the results of the clinical trials for Silenor, the timing of the interpretation of such results and the FDA's agreement with such interpretation; the potential for Somaxon to make a resubmission to the Silenor NDA; the potential for Silenor to receive regulatory approval for one or more indications on a timely basis or at all; the potential for the FDA to impose non-clinical, clinical or other requirements to be completed before or after regulatory approval of Silenor; Somaxon's ability to demonstrate to the satisfaction of the FDA that potential NDA approval of Silenor is appropriate prior to the completion of standard, long-term carcinogenicity studies, given the context of completed trials and pending studies; the timing and results of non-clinical studies for Silenor, and the FDA's agreement with Somaxon's interpretation of such results; Digital50.com Digital 50 Daily Industry News RSS Feed
View all